Tate & Lyle shareholders accept Ingredion's 595 pence cash offer
Tate & Lyle shareholders approved Ingredion's 595 pence per share cash acquisition offer. The transaction, announced in June 2026, projects $130 million in synergies by 2030 and aims for completion in the second half of 2027 pending regulatory clearances.

*this image is generated using AI for illustrative purposes only.
Tate & Lyle PLC shareholders have accepted Ingredion Incorporated’s recommended all-cash offer to acquire the entire issued and to be issued share capital of the British ingredient solutions provider. The acceptance, confirmed on July 28, 2026, marks a critical milestone in the transaction originally announced on June 8, 2026. This approval paves the way for the creation of a combined global leader in food, beverage, pharmaceutical, and personal care ingredients, carrying significant strategic weight for enhanced innovation capabilities and market position.
The offer price stands at 595 pence per share in an all-cash structure. Jim Zallie, chairman, president and CEO of Ingredion, stated that the shareholder vote reflects confidence in the combined entity’s ability to drive future growth. "Today marks an important milestone toward establishing a global leader in ingredient solutions that will help create the future of food," Zallie said. The Board of Directors of Tate & Lyle had previously recommended the offer to its shareholders, facilitating the acceptance process.
Financial Synergies and Value Creation
Ingredion projects substantial financial benefits from the merger, centered on operational efficiencies and earnings accretion. The company expects to achieve run-rate net cost synergies of approximately $130 million, with full realization targeted by the end of 2030. These synergies are expected to drive adjusted EPS accretion for Ingredion shareholders in the first year following completion. Furthermore, the combined group anticipates an enhanced long-term growth profile and improved earnings potential, leveraging complementary capabilities in formulation and product development.
| Metric | Value / Target | Timeline |
|---|---|---|
| Offer Price | 595 pence per share | July 28, 2026 (Acceptance) |
| Net Cost Synergies | $130 million (run-rate) | By end of 2030 |
| EPS Impact | Accretive | First year post-completion |
| Expected Closing | N/A | H2 2027 |
Regulatory Path and Integration
Despite shareholder approval, the transaction remains subject to regulatory review and clearance as outlined in the scheme document. Ingredion confirmed that it continues to operate as a separate business from Tate & Lyle until the deal closes. Regulatory approvals are ongoing, with management focused on securing necessary clearances efficiently. The company has indicated that closing is expected in the second half of 2027, assuming all conditions are satisfied.
Zallie emphasized the strategic rationale behind the merger, noting that combining Ingredion’s and Tate & Lyle’s capabilities will strengthen their ability to solve complex formulation challenges. "We will strengthen our ability to help customers solve complex formulation challenges with an expanded innovation engine to accelerate product development," he added. The integration aims to deliver healthier, affordable, and high-quality food products to consumers globally.
What the Numbers Show
The commitment to $130 million in net cost synergies by 2030 suggests a disciplined approach to post-merger integration, focusing on operational efficiency rather than immediate revenue scaling. With Ingredion reporting 2025 annual net sales of approximately $7.2 billion, the addition of Tate & Lyle represents a significant expansion of its addressable market. The accretive nature of the deal in the first year indicates that the projected synergies are expected to outweigh integration costs quickly, providing early value to shareholders while the longer-term growth profile matures.
How might the anticipated $130 million in net cost synergies impact Ingredion's capital allocation strategy and dividend policy post-integration?
What specific regulatory hurdles in key markets like the EU or China could potentially delay the expected H2 2027 closing date?
How will the combined entity's expanded innovation engine address the growing consumer demand for clean-label and functional ingredients?




























